PIK3CA and breast cancer: Responses to alpelisib were not significantly different when analyzing only BC PDX (Fig. 4b); however, when considering pan-cancer PDX we observed significantly better responses in tumors with PIK3CA-mut/gain compared to PIK3CA-mut/neut (p = 0.023) (supplementary Fig. 6b).